TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06330948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SugarCut® Unripe Guava Fruit Extract
Description: This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the SugarCut® Guava Extract group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
Study: NCT06336798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg
Description: Study participants will take Pioglitazone 30 mg PO daily
Study: NCT06630637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness intervention
Description: 90 minutes of strength and/or cardiovascular training for a minimum of 5 days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold & heat intervention
Description: Cold plunge: at least 3 days per week, 2 sessions of maximum 5 minutes each (minimum 2 minutes between sessions) at a minimum of 6 degrees Celsius. Potential inclusion of GKI measurements before and after plunge.~Heat Therapy: maximum of 2 sessions of 20 minutes each of dry sauna blanket (minimum 5 minutes break between sessions) following the cold plunge intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airofit
Description: Airofit is a smart breathing training device designed to improve respiratory strength and efficiency. It is used for enhancing sport performance, well-being, and overall health. The device works by providing adjustable resistance to breathing muscles.~5-10 minutes of daily use.
Study: NCT06336798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg
Description: Study participants will take Pioglitazone 30 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will take a placebo PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will take a placebo PO daily
Study: NCT06630637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 18h fasting
Description: Minimum of 18 hours fasting per day, with feeding window to occur between 5pm-8pm or 12pm-3pm. The fasting procedures will occur only after the Three Meal Phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 48h fasting
Description: 48h fasting maximum twice monthly, at least one week apart. Multivitamin and electrolytes with water, and black coffee or tea (0-calorie drinks) will be consumed.The fasting procedures will occur the Three Meal Phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three meal phase
Description: During the first week of the study, the participant will follow a regime of three meals per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean-inspired diet
Description: Regimen of Mediterranean-inspired nutrition comprised of Olive Oil, Olives, Leafy Green Vegetables, Lean Protein (Beef, Chicken, Lamb, Pork, Duck, Salmon, Tuna), Chia Seeds, Pecans, Macadamia, Pumpkin Seeds, Walnuts, Greek Yogurt, Salt, Pepper, Paprika, Cumin, Garlic powder, onion powder; Fruit: Blueberry, Grapefruit; Carbohydrates: Rolled Oats; Hydration: Water, Black Coffee, Black Tea, Coke Zero and 100 Zero sparingly, Ultima electrolytes.~Photographs of meals will be taken to create a visual record of the diet followed. Photographs of the devices will be taken to create a visual record of the blood glucose and ketone concentration results.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplements
Description: Multivitamin (Centrum), Vitamin D (Up to 2000 IU per day), Creatine (Up to 2000mg), Fisetin (1 pill), Omega-3 (1 tablet), Turmeric, Pre-Probiotic, Blueberry Extract, Holy Basil Extract.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generative AI
Description: Feeding ketone data, glucose data (from finger prick and/or CGM), any/all Apple Watch Data, and dietary images into a generative AI platform to convert data into images using any selected prompts, with the intent of the images serving as immediate, visual readouts as a function of activity and/or inactivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Three interviews, of 30-60 minutes each one, at baseline, end of three meal phase and end of study, to gain insights into the participant's experience. Exploration of daily routines including diet, exercise and the use of technology and aspects of a healthy lifestyle.
Study: NCT05070104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: 250-1000mg/m2 -14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FFX
Description: Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV
Study: NCT05000450

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-605
Description: ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study: NCT05599399

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gum acacia
Description: 25 grams of gum acacia powder is administered on daily-basis
Study: NCT06009419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
Study: NCT06431035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeine
Description: The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
Study: NCT04338165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML [Repatha]
Description: 3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
Study: NCT04881799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine/Topiramate (Qsymia)
Description: Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentermine/Topiramate (Qsymia)
Description: Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily injection
Study: NCT06157879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WVI-MIS-01-2022
Description: Microwave scans
Study: NCT05085184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UI018
Description: Test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co-administration of UIC201806 and UIC201602
Description: Reference
Study: NCT06421948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib and chidamide
Description: A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
Description: A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
Study: NCT05725018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EB-101 Surgical application of RDEB wounds
Description: EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]
Study: NCT04456920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone consultation
Description: At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PRO self-completed via connected objects (tablet/phone)
Description: Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone consultation
Description: At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
Study: NCT06336798

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Labs
Description: Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Labs
Description: Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
Study: NCT05248386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-GRT7039
Description: RTX-GRT7039 intra-articular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Study: NCT04964063

Intervention type: OTHER
Group type: OTHER
Intervention: Potassium Nitrate + Sodium Fluoride
Description: Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
Study: NCT06553924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan and Tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan and Tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrOpsynvi® macitentan and tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrOpsynvi® macitentan and tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study: NCT06499545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release
Description: Release of pre-pressure at the latent trigger point of flexor digitorum brevis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non emision Laser
Description: Non emision laser in Flexor digitorum brevis latent trigger point
Study: NCT04951336

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FoTv
Description: Fomitopsis Officinalis and Trametes Versicolor

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FoTv
Description: Fomitopsis Officinalis and Trametes Versicolor
Study: NCT06317857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centio Forte
Description: A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centio Forte
Description: A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
Study: NCT04615962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Acetate 1% Cream
Description: Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate
Description: Mometasone is a medium-strength corticosteroid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNG100
Description: A combination of low potency steroid and skin barrier repair agent
Study: NCT04628806

Intervention type: DIAGNOSTIC_TEST
Intervention: CTC isolation by HSP70
Description: patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
Study: NCT05129306

Intervention type: OTHER
Intervention: Observational
Description: In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
Study: NCT04946214

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smart Water Bottle
Description: Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
Study: NCT04936555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Acupressure
Description: Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
Study: NCT05517603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AJ201
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04638309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-548 + Azacitidine
Description: APR-548 monotherapy period followed by APR-548 in combination with Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-548 + Azacitidine
Description: APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
Study: NCT04456920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone consultation
Description: At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visit
Description: And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visit
Description: And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
Study: NCT06202118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study: NCT06106659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini Midline
Description: The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector.

Intervention type: DEVICE
Group type: OTHER
Intervention: Mini Midline
Description: The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector.
Study: NCT06631365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrEPsmart mobile app
Description: The PrEPsmart mobile app is an innovative and comprehensive app to support sexual minority men (SMM) using on-demand pre-exposure prophylaxis (PrEP) or daily PrEP. The PrEPsmart app consists of the following components:~1. PrEP 211 dosing/sex diary and reminders~2. Feedback on PrEP protection levels~3. Quick tips~4. Bi-directional secure messaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
Study: NCT04895007

Intervention type: BIOLOGICAL
Intervention: Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine
Description: Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.

Intervention type: BIOLOGICAL
Intervention: Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine
Description: Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.

Intervention type: BIOLOGICAL
Intervention: Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine
Description: Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.